Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Oncolytics Biotech Inc. (T.ONC) had Return on Equity of 757.01% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-40.20M |
|
-- |
|
-- |
|
-- |
|
-40.30M |
|
-- |
|
-40.09M |
|
-40.09M |
|
-40.20M |
|
-40.20M |
|
-40.20M |
|
-40.20M |
|
-40.30M |
|
-39.80M |
|
95.86M |
|
95.86M |
|
-0.42 |
|
-0.42 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
10.60M |
|
-- |
|
-- |
|
-- |
|
15.91M |
|
-5.31M |
|
-5.31M |
|
-5.31M |
|
108.02M |
|
| Cash Flow Statement Financials | |
-28.11M |
|
-0.01M |
|
19.74M |
|
15.49M |
|
7.27M |
|
-8.21M |
|
4.34M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.12 |
|
-- |
|
-- |
|
-0.11 |
|
-0.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-28.12M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
757.01% |
757.01% |
|
-379.31% |
|
838.70% |
|
-0.05 |
|
-0.29 |
|
-0.29 |
|